Vaccine+HBIG Versus Vaccine+Placebo for Newborns of HBsAg+ Mothers

This study has been completed.
Sponsor:
Collaborators:
Indian Council of Medical Research
Lady Hardinge Medical College
Information provided by:
Govind Ballabh Pant Hospital
ClinicalTrials.gov Identifier:
NCT01412567
First received: August 8, 2011
Last updated: NA
Last verified: August 2011
History: No changes posted
  Purpose

Prevention of perinatal transmission is essential to decrease the global burden of chronic HBV. Recombinant HBV vaccine and hepatitis B immunoglobulin (HBIG) given after delivery to the newborns of HBsAg positive mothers is the standard of care for prevention of HBV in babies. Some studies have however, shown that vaccine alone may be equally effective. Hence, immunoprophylaxis with hepatitis B vaccine with or without HBIG is effective in prevention of transmission of overt HBV infection to the babies. The primary outcome measure of most of the trials on immunoprophylaxis was the occurrence of hepatitis B, defined as a blood specimen positive for hepatitis B surface antigen (HBsAg). However, whether this immunoprophylaxis also prevents HBsAg negative HBV infection (occult HBV infection) in babies is not known. In the present study the investigators evaluated the efficacy of the two regimens; vaccination alone and compared it with vaccination plus HBIG administration at birth in preventing transmission of both overt and occult HBV infection to the newborn babies.


Condition Intervention
Chronic Hepatitis B
Drug: Vaccine+HBIG
Drug: Vaccine+Placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Single Group Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Prevention
Official Title: Comparison of Recombinant Hepatitis B Vaccine Plus Hepatitis B Immune Globulin (HBIG) Versus Vaccine Plus Placebo for Prophylaxis of Hepatitis B Infection in Newborns of Hepatitis B Surface Antigen (HBsAg) Positive Mothers

Resource links provided by NLM:


Further study details as provided by Govind Ballabh Pant Hospital:

Primary Outcome Measures:
  • remaining free of any HBV infection (either overt or occult) plus development of adequate immune response to vaccine at 18 weeks of age [ Time Frame: 18 weeks ] [ Designated as safety issue: No ]

Enrollment: 259
Study Start Date: October 2005
Study Completion Date: June 2010
Primary Completion Date: June 2010 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Vaccine+HBIG Drug: Vaccine+HBIG
Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS HBIG in the dose of 0.5 mL intramuscularly immediately after birth
Placebo Comparator: Vaccine+Placebo Drug: Vaccine+Placebo
Recombinant hepatitis B vaccine at birth, 6 weeks, 10 weeks, and 14 weeks in the dose of 10 mcg (0.5 mL), by intramuscular injection in the anterolateral thigh; PLUS placebo intramuscularly immediately after birth

  Eligibility

Ages Eligible for Study:   up to 1 Day
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • Newborn babies of mothers who were found to be HBsAg positive

Exclusion Criteria:

  • Babies of mothers who had any symptoms of liver disease during the pregnancy such as jaundice, pruritus, ascites, or gastrointestinal bleed;
  • Babies of mothers taking anti-viral treatment during pregnancy;
  • Babies of mother with pregnancy related complications; and
  • Babies of mothers who refused to participate in the study.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT01412567

Locations
India
Lady Hardinge Medical College
New Delhi, Delhi, India, 110001
Sponsors and Collaborators
Govind Ballabh Pant Hospital
Indian Council of Medical Research
Lady Hardinge Medical College
  More Information

No publications provided by Govind Ballabh Pant Hospital

Additional publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: Prof Shiv Kumar Sarin, G B Pant Hospital
ClinicalTrials.gov Identifier: NCT01412567     History of Changes
Other Study ID Numbers: LHMC-1
Study First Received: August 8, 2011
Last Updated: August 8, 2011
Health Authority: India: Indian Council of Medical Research

Keywords provided by Govind Ballabh Pant Hospital:
Hepatitis B
HBsAg
Antenatal
Pregnancy
Vertical transmission
Placenta
HBV DNA

Additional relevant MeSH terms:
Hepatitis
Hepatitis A
Hepatitis B
Hepatitis, Chronic
Hepatitis B, Chronic
Liver Diseases
Digestive System Diseases
Hepatitis, Viral, Human
Virus Diseases
Enterovirus Infections
Picornaviridae Infections
RNA Virus Infections
Hepadnaviridae Infections
DNA Virus Infections

ClinicalTrials.gov processed this record on July 20, 2014